Hepatitis Forums

Hepatitis C Main Forums => Hepatitis C Research News & Studies => Topic started by: Hep Editors on August 13, 2018, 10:30:14 am

Title: Zepatier Plus Sovaldi Beats Hep C in Those With Cirrhosis and Genotype 3
Post by: Hep Editors on August 13, 2018, 10:30:14 am

Merck’s Zepatier (grazoprevir/elbasvir) plus Gilead Sciences’ Sovaldi (sofosbuvir), with or without ribavirin, cured genotype 3 of hepatitis C virus (HCV) at high rates in a recent trial.

Publishing their findings in the journal Hepatology, researchers conducted a Phase II randomized open-label study, known as C-ISLE, of Zepatier plus Sovaldi with or without ribavirin among those with genotype 3 of HCV and compensated cirrhosis (the milder form of the severe liver disease).

Read more...
https://www.hepmag.com/article/zepatier-plus-sovaldi-beats-hep-c-cirrhosis-genotype-3